acarbose/gin diare

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 44 rezilta yo

Acarbose related diarrhea: increased butyrate upregulates prostaglandin E.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The alpha-glucosidase inhibitor acarbose is a drug used to treat type II diabetes mellitus. It occasionally causes diarrhea. Acarbose related colitis has been reported. This note explains how such side effects may occur. Because of small intestine alpha-glucosidase inhibition, increased starch

Use of the alpha glucosidase inhibitor acarbose in patients with 'Middleton syndrome': normal gastric anatomy but with accelerated gastric emptying causing postprandial reactive hypoglycemia and diarrhea.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Postprandial reactive hypoglycemia, early satiety and diarrhea are well-recognized side effects following full or partial gastrectomy or gastric bypass. It has only recently been realized, however, that patients with normal gastric anatomy may experience similar symptoms and signs due to primary

Essential oil of Zygophyllum album inhibits key-digestive enzymes related to diabetes and hypertension and attenuates symptoms of diarrhea in alloxan-induced diabetic rats.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Zygophyllum album L. (Zygophyllaceae), commonly known as Bougriba, is widely used to treat diabetes, digestive tract spasm, and hypertension in folk medicine, in Tunisia. OBJECTIVE This study investigates the antidiabetic, antidiarrheal, and antihypertensive activities of the leaves of

A novel synergistic galactomannan-based unit dosage form for sustained release of acarbose.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In the current study, the potential of a novel combination of a galactomannan with acarbose (100 mg) was evaluated for attaining a desired hypoglycaemic effect over a prolonged period of time. Three major antidiabetic galactomannans viz., fenugreek gum, Boswellia gum, and locust bean gum were

Acarbose in the treatment of type I diabetes.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE This 36-week multicenter double-blind placebo-controlled study was designed to assess the safety and efficacy of acarbose, administered in conjunction with diet and insulin therapy, for the treatment of patients with type I diabetes. METHODS Acarbose was administered using a forced

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Acarbose delays release of glucose from complex carbohydrates and disaccharides by inhibiting intestinal alpha-glucosidases, thereby attenuating postprandial increments in blood glucose and insulin. This multicenter, double-blind, placebo-controlled study compared the efficacy and safety

Pneumatosis coli induced by acarbose administration for diabetes mellitus. Case report and literature review.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The authors report a case report of rare disease interesting the digestive tract and often associated to the other gastrointestinal pathologies and/or pulmonary diseases and can be also associated to not gastrointestinal conditions such as collagen-vascular disease, transplantation, AIDS, use of

A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To determine whether a forced titration of acarbose (from 50 to 300 mg three times daily) administered over a 24-week period, in conjunction with diet and insulin therapy, improves glycemic control and reduces daily insulin requirements in insulin-requiring type II diabetes. METHODS This

A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

To evaluate the safety and efficacy of sitagliptin when added to the treatment of patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on acarbose monotherapy. This was a multicenter, randomized, placebo-controlled, double-blind clinical trial. Patients (N = 381) with T2DM

[Medication-related diarrhea].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Numerous medications can trigger diarrhea. In some cases it is a common side effect, and the relationship is evident (e.g. acarbose, somatostatin analogs and antibiotics). When diarrhea does occur, the therapeutic benefit of the drug should be weighed against the negative results of the side effect.

The effect of acarbose on the colonic transit time of elderly long-term care patients with type 2 diabetes mellitus.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Constipation is common in elderly patients with diabetes mellitus (DM); its prevalence is estimated as up to 60% among patients with diabetic neuropathy. Acarbose, an alpha-glucosidase inhibitor, has a beneficial role in controlling DM, although one of its side effects is diarrhea. This

[Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Only few controlled studies have been conducted on the influence of additive treatment with the glucosidase inhibitor acarbose on post-prandial blood sugar levels in insulin-dependent diabetics. To date, the behavior of blood sugar levels under treatment with acarbose has not been studied in

A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To determine the degree to which alpha-glucosidase inhibitors, with their unique mode of action primarily reducing postprandial hyperglycemia, offer an additional therapeutic approach in the long-term treatment of type 2 diabetes. METHODS We studied 1,946 patients (63% men) who were

Effect of long-term treatment with insulin and/or acarbose on glomerular basement membrane thickening in alloxan-diabetic rats.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Acarbose is a competitive inhibitor of the intestinal alpha-glycosidases, that can delay absorption of intestinal carbohydrates causing their malabsorption. In the present paper we studied the effects of insulin, acarbose and their association on glomerular basement membrane thickening in

Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To assess the efficacy of acarbose monotherapy during 12-weeks treatment on the fasting glycemic level, lipid and lipoproteins profiles, in patients with type 2 diabetes mellitus. METHODS Type 2 diabetics were selected from out patient department of Baqai Diabetes and Endocrine Centre, and

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye